Usefulness of KL-6 in the subtyping of intraductal papillary mucinous neoplasia of the pancreas, including carcinoma, dysplasia, and hyperplasia

KL-6 is known as a useful serum biomarker of the disease activity in interstitial pneumonias. We investigated its usefulness as a biomarker for subtyping intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. IPMNs are generally divided into 4 subtypes, namely pancreatobiliary (PB), intes...

Full description

Saved in:
Bibliographic Details
Published in:Medical molecular morphology 2015-06, Vol.48 (2), p.85-91
Main Authors: Ohtsuki, Yuji, Watanabe, Ryohei, Kimura, Masashi, Nomura, Katsuyoshi, Maeda, Tomoharu, Kito, Katsumi, Takeji, Miyuki, Lee, Gang-Hong, Furihata, Mutsuo
Format: Article
Language:English
Subjects:
Adenocarcinoma, Mucinous - metabolism
Adenocarcinoma, Mucinous - pathology
Aged
Aged, 80 and over
Anatomy
Antibodies - immunology
Biomarkers
Biomarkers - metabolism
Carcinoma, Pancreatic Ductal - metabolism
Carcinoma, Pancreatic Ductal - pathology
Carcinoma, Papillary - metabolism
Carcinoma, Papillary - pathology
Female
Humans
Hyperplasia - metabolism
Hyperplasia - pathology
Immunohistochemistry
Immunohistochemistry - methods
Male
Medicine
Medicine & Public Health
Middle Aged
Molecular Medicine
Mucin-1 - metabolism
Neoplasm Invasiveness - pathology
Original Paper
Pancreas
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - pathology
Pathology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:KL-6 is known as a useful serum biomarker of the disease activity in interstitial pneumonias. We investigated its usefulness as a biomarker for subtyping intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. IPMNs are generally divided into 4 subtypes, namely pancreatobiliary (PB), intestinal (INT), gastric (GS), and oncocytic (ONC). Aside from the KL-6 antibody, the MUC1, MUC2, MUC5AC, MUC6, and MIB-1 antibodies were also examined. Eighteen IPMN cases were examined, including 12 cases of intraductal papillary mucinous carcinomas (IPMCs) simultaneously associated with dysplasia (IPMDs) and hyperplasia (IPMHs) and 6 IPMD cases with IPMH. KL-6 antibody was positive in the 8 IPMC cases, corresponding to a MUC2-negative PB subtype, but negative in 4 IPMC cases, corresponding to the INT subtype, which is positive for MUC2. IPMD of moderate-to-severe degree positively stained for the KL-6 antibody in the IPMC cases of the PB subtype but not in those of the INT subtype. The IPMH cases were mostly negative for KL-6, similar to the mild IPMD cases. In the 6 cases of mild IPMD and/or IPMH, KL-6 and MUC2 expressions were mostly negative. In conclusion, the KL-6 antibody is immunohistochemically a good biomarker of the PB subtype of IPMC, but not the INT subtype. Identifying IPMN subtypes based on KL-6 stainability would be useful. Clinicopathological studies with more IPMC cases might be needed for further progress in this field of study.
ISSN:1860-1480
1860-1499
DOI:10.1007/s00795-014-0080-1